Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Neurology

What Is Axonal Loss in MMN? Nerve Damage Explained

At a Glance

In MMN, axonal loss means the inner fibers of motor nerves have been damaged or destroyed, disconnecting some muscle fibers and causing weakness or atrophy. IVIg may protect surviving axons, but it cannot restore axons already lost.

In Multifocal Motor Neuropathy (MMN), axonal loss refers to the damage and death of the inner “wire” of the nerve (the axon). In MMN, the immune system typically attacks the nerve in a way that blocks the signal (conduction block). However, in some patients, severe or ongoing immune activity can lead to the breakdown of the axon itself [1][2]. When axons are lost, it may leave lasting muscle weakness and atrophy (shrinking) that treatments like intravenous immunoglobulin (IVIg) generally cannot reverse [3][4].

The Spectrum of Nerve Injury

To understand axonal loss, it helps to picture a nerve like an electrical cable: it has an inner wire (the axon) that carries signals from your spinal cord to your muscles, and outer insulation (the myelin sheath).

In MMN, your immune system mistakenly attacks specific parts of the motor nerves [4][5]. This can create a conduction block—meaning the nerve signal is stopped or slowed, but the inner axon may still be physically intact [6]. Conduction blocks can often be improved or reversed with treatment [7].

However, if the immune-mediated injury is severe or prolonged, the axon itself can degenerate [1][2]. Conduction block and axonal loss often coexist, and the condition exists on a spectrum that varies widely from person to person [1].

How Axonal Loss Affects Your Muscles

An axon connects the nerve to a group of muscle fibers, forming a motor unit. When an axon dies, those specific muscle fibers no longer receive signals, leading to fewer working motor units [8][9].

This loss of connection can cause two primary issues:

  • Persistent Weakness: Without a working nerve connection, the affected muscle fibers cannot contract. While a lost axon will not grow back, you may still see some functional improvement through the remaining healthy nerves.
  • Muscle Atrophy: Muscles need regular nerve signals to maintain their size. When axons are lost, affected muscles may shrink—a process called atrophy [10]. Note that atrophy can also be influenced by disuse, so visible shrinking doesn’t always mean the damage is entirely permanent.

Your body also has a built-in way to compensate. Surviving healthy nerves can branch out to connect with abandoned muscle fibers, a process called reinnervation [8]. Reinnervation is an important mechanism that helps preserve muscle function and strength, even though it cannot fully replace all the lost motor units [8][9].

Treatment Goals and Testing

Doctors monitor the health of your nerves using a combination of tests. Nerve conduction studies (NCS) measure how well signals travel and help identify conduction block, while a needle EMG looks at the electrical activity in the muscle itself to find signs of active nerve damage and reinnervation [4][8]. These tests provide indirect evidence of nerve health and are combined with your clinical exam to understand your specific situation.

Treatment with IVIg is immunomodulatory, meaning it helps adjust the immune system’s activity [7]. For many patients, prompt and consistent IVIg therapy can improve conduction, restore strength, and limit further axonal injury [7][3]. However, because IVIg cannot restore lost axons, weakness caused by established axonal loss is often persistent [3][11][4]. Additionally, MMN can sometimes slowly progress despite appropriate maintenance therapy [3].

This is why neurologists focus so heavily on early recognition and ongoing treatment: the goal is to protect your surviving nerves. Always report new or rapidly worsening weakness to your neurology team, and do not change or delay your infusions without medical advice. While reading about permanent nerve damage can be frightening, remember that your prognosis is highly individual. An individualized plan including physical or occupational therapy can help you safely maximize your remaining strength and maintain independence.

Common questions in this guide

What does axonal loss mean in multifocal motor neuropathy?
Axonal loss means the inner fibers of some motor nerves have been damaged or destroyed. This can disconnect muscle fibers from their nerve signals, causing persistent weakness and muscle wasting that IVIg generally cannot reverse.
How is axonal loss different from conduction block in MMN?
Conduction block means a nerve signal is stopped or slowed even though the nerve fiber may still be intact. Axonal loss is physical degeneration of the nerve fiber itself, and both problems can occur together.
Can IVIg reverse axonal loss in MMN?
IVIg can improve nerve signal conduction, restore some strength, and help limit further nerve injury in many patients. It cannot restore axons that have already been lost, so weakness from established axonal loss may persist.
How do doctors test for axonal loss in MMN?
Nerve conduction studies assess how signals travel through the nerves and can help identify conduction block. A needle EMG measures electrical activity in muscles and can provide signs of active nerve damage and reinnervation; doctors interpret these results with the clinical examination.
Does axonal loss always cause permanent weakness or muscle atrophy?
A lost axon does not usually grow back, so weakness caused by established axonal loss is often lasting. Surviving nerves may partly reconnect with abandoned muscle fibers, and physical or occupational therapy can help maximize remaining function.

Get notified when new evidence is published on Multifocal motor neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Nodopathies of the peripheral nerve: an emerging concept.

    Uncini A, Kuwabara S

    Journal of neurology, neurosurgery, and psychiatry 2015; (86(11)):1186-95 doi:10.1136/jnnp-2014-310097.

    PMID: 25699569
  2. 2

    Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy.

    Tracy JA, Taylor BV, Kiernan M, et al.

    Journal of clinical neuromuscular disease 2020; (22(1)):1-10 doi:10.1097/CND.0000000000000279.

    PMID: 32833719
  3. 3

    Prevention of axonal loss after immediate dosage titration of immunoglobulin in multifocal motor neuropathy.

    Al-Zuhairy A, Jakobsen J, Krarup C

    European journal of neurology 2024; (31(7)):e16305 doi:10.1111/ene.16305.

    PMID: 38651498
  4. 4

    Revisiting multifocal motor neuropathy: mechanisms, diagnosis and future directions.

    Dubuisson NJ, Rajabally YA, Philips C, et al.

    Brain : a journal of neurology 2026; doi:10.1093/brain/awag260.

    PMID: 42522566
  5. 5

    The pathogenesis of multifocal motor neuropathy and an update on current management options.

    Léger JM, Guimarães-Costa R, Iancu Ferfoglia R

    Therapeutic advances in neurological disorders 2015; (8(3)):109-22 doi:10.1177/1756285615575269.

    PMID: 25941538
  6. 6

    Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model.

    Harschnitz O, van den Berg LH, Johansen LE, et al.

    Annals of neurology 2016; (80(1)):71-88 doi:10.1002/ana.24680.

    PMID: 27130524
  7. 7

    Immunoglobulin for multifocal motor neuropathy.

    Keddie S, Eftimov F, van den Berg LH, et al.

    The Cochrane database of systematic reviews 2022; (1()):CD004429 doi:10.1002/14651858.CD004429.pub3.

    PMID: 35015296
  8. 8

    Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss.

    Garg N, Howells J, Yiannikas C, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2017; (128(10)):2022-2028 doi:10.1016/j.clinph.2017.07.414.

    PMID: 28837908
  9. 9

    Motor unit integrity in multifocal motor neuropathy: A systematic evaluation with CMAP scans.

    Stikvoort García DJL, Kovalchuk MO, Goedee HS, et al.

    Muscle & nerve 2022; (65(3)):317-325 doi:10.1002/mus.27469.

    PMID: 34854491
  10. 10

    Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment.

    Löscher WN, Oberreiter EM, Erdler M, et al.

    Journal of neurology 2018; (265(12)):2834-2840 doi:10.1007/s00415-018-9071-9.

    PMID: 30259176
  11. 11

    Immunoglobulin therapy in the treatment of multifocal motor neuropathy.

    Kumar A, Patwa HS, Nowak RJ

    Journal of the neurological sciences 2017; (375()):190-197 doi:10.1016/j.jns.2017.01.061.

    PMID: 28320129

This page explains axonal loss and nerve testing in MMN for educational purposes and does not replace medical advice. Ask your neurologist how your test results and treatment plan apply to you.